The FDA has approved a 180-day supplement application for VisionCare Ophthalmic Technologies' PMA 180-day supplement application of the implantable miniature telescope for use in patients with end-stage age-related macular degeneration who are 65 years and older. The telescope implant is integral to the CentraSight treatment program, VisionCare said, which is proven to restore vision and improve quality of life in older adults with end stage AMD. According to the company, it is the only FDA-approved surgical device for end-stage AMD and is Medicare eligible. Read More
